Tag Archives: Tekturna HCT

April 2012 Safety Labeling Changes

Share

translation servicesTranslate | French translation Spanish translation translate German translate Chinese The MedWatch April 2012 Safety Labeling Changes posting includes¬†43 products with safety labeling changes to the following sections: BOXED WARNINGS, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS and PATIENT PACKAGE INSERT.¬† … Continue reading

Share
Posted in FDA 2012, FDA Label Change, FDA Safety Communication | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off

Aliskiren containing Medications Drug Safety Comunication

Share

translation servicesTranslate | French translation Spanish translation translate German translate ChineseAliskiren-containing Medications: Drug Safety Comunication – New Warning and Contraindication including: Amturnide (aliskiren hemifumarate, amlodipine besylate, and hydrochlorothiazide) Tekturna (aliskiren hemifumarate) Tekturna HCT (aliskiren hemifumarate and hydrochlorothiazide) Tekamlo (aliskiren hemifumarate … Continue reading

Share
Posted in Endocrinology, FDA 2012, FDA Safety Communication, Internal Medicine, Pharmacy | Tagged , , , , , , , , , , , , , , , , | Comments Off